KR20240099410A - 신규한 폴리펩티드 - Google Patents

신규한 폴리펩티드 Download PDF

Info

Publication number
KR20240099410A
KR20240099410A KR1020247018489A KR20247018489A KR20240099410A KR 20240099410 A KR20240099410 A KR 20240099410A KR 1020247018489 A KR1020247018489 A KR 1020247018489A KR 20247018489 A KR20247018489 A KR 20247018489A KR 20240099410 A KR20240099410 A KR 20240099410A
Authority
KR
South Korea
Prior art keywords
polypeptide
domain
mutation
mutations
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018489A
Other languages
English (en)
Korean (ko)
Inventor
샨트스 라우라 본
바르나바스 니에시가
마티아스 레빈
안나 셀
Original Assignee
엘리게이터 바이오사이언스 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2204539.7A external-priority patent/GB202204539D0/en
Priority claimed from GBGB2212801.1A external-priority patent/GB202212801D0/en
Application filed by 엘리게이터 바이오사이언스 에이비 filed Critical 엘리게이터 바이오사이언스 에이비
Publication of KR20240099410A publication Critical patent/KR20240099410A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247018489A 2021-11-05 2022-11-04 신규한 폴리펩티드 Pending KR20240099410A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2115925.6 2021-11-05
GB202115925 2021-11-05
GB2204539.7 2022-03-30
GBGB2204539.7A GB202204539D0 (en) 2022-03-30 2022-03-30 Novel peptides
GBGB2212801.1A GB202212801D0 (en) 2022-09-02 2022-09-02 Novel peptides
GB2212801.1 2022-09-02
PCT/EP2022/080860 WO2023079101A2 (en) 2021-11-05 2022-11-04 Novel polypeptides

Publications (1)

Publication Number Publication Date
KR20240099410A true KR20240099410A (ko) 2024-06-28

Family

ID=84329469

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247018489A Pending KR20240099410A (ko) 2021-11-05 2022-11-04 신규한 폴리펩티드
KR1020247018934A Pending KR20240114794A (ko) 2021-11-05 2022-11-04 신규 펩티드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247018934A Pending KR20240114794A (ko) 2021-11-05 2022-11-04 신규 펩티드

Country Status (9)

Country Link
US (4) US20260001961A1 (cg-RX-API-DMAC7.html)
EP (2) EP4426733A2 (cg-RX-API-DMAC7.html)
JP (2) JP2024542142A (cg-RX-API-DMAC7.html)
KR (2) KR20240099410A (cg-RX-API-DMAC7.html)
AU (1) AU2022381977A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237463A1 (cg-RX-API-DMAC7.html)
IL (1) IL312556A (cg-RX-API-DMAC7.html)
MX (1) MX2024005508A (cg-RX-API-DMAC7.html)
WO (2) WO2023079102A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260001961A1 (en) * 2021-11-05 2026-01-01 Alligator Bioscience Ab Novel polypeptides
JP2026515781A (ja) * 2023-04-13 2026-05-19 アリゲーター・バイオサイエンス・アーベー 併用療法
CN117924468B (zh) * 2023-12-08 2024-09-20 南京大学 一种靶向登革热病毒ns1蛋白纳米抗体的制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
CA2980189A1 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EP3898681A2 (en) * 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptides
GB201820556D0 (en) 2018-12-17 2019-01-30 Alligator Bioscience Ab Novel polypeptides
AU2020357944A1 (en) * 2019-09-30 2022-03-31 Adimab, Llc CH1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same
EP4048701A4 (en) 2019-10-23 2024-05-29 Lyvgen Biopharma Holdings Limited Anti-cd40 binding molecules and bi-specific antibodies comprising such
KR20220147583A (ko) * 2020-01-09 2022-11-03 바이오뮤넥스 파마슈티컬스 Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체
US20260001961A1 (en) * 2021-11-05 2026-01-01 Alligator Bioscience Ab Novel polypeptides

Also Published As

Publication number Publication date
JP2024542142A (ja) 2024-11-13
WO2023079101A3 (en) 2023-06-15
JP2024543043A (ja) 2024-11-19
IL312556A (en) 2024-07-01
US20260001961A1 (en) 2026-01-01
AU2022381977A1 (en) 2024-05-23
KR20240114794A (ko) 2024-07-24
US11873348B2 (en) 2024-01-16
EP4426738A2 (en) 2024-09-11
US20260146107A1 (en) 2026-05-28
WO2023079101A2 (en) 2023-05-11
EP4426733A2 (en) 2024-09-11
US20240117074A1 (en) 2024-04-11
US12448465B2 (en) 2025-10-21
US20230312754A1 (en) 2023-10-05
MX2024005508A (es) 2024-09-18
CA3237463A1 (en) 2023-05-11
WO2023079102A2 (en) 2023-05-11
WO2023079102A3 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US11629189B2 (en) Bispecific antibody for ICOS and PD-L1
TWI810541B (zh) 靶向ox40及fap之雙特異性抗原結合分子
JP7425604B2 (ja) 抗ctla4-抗pd-1二機能性抗体、その医薬組成物および使用
KR102427192B1 (ko) 항-인간 4-1bb 항체 및 그의 용도
CN110066338B (zh) 作为T细胞衔接器的双特异性IgG抗体
WO2020098734A1 (zh) 抗tigit抗体及其用途
CN111542546B (zh) 抗lag-3抗体及其用途
US20170304437A1 (en) Bispecific molecules capable of specifically binding to both ctla-4 and cd40
TW201930353A (zh) 使用經靶向之ox40促效劑的組合療法
US12570759B2 (en) Polypeptides
CN114763385B (zh) 靶向ror1的抗体及其用途
WO2018036472A1 (zh) 一种抗pd1单克隆抗体、其药物组合物及其用途
US20260001961A1 (en) Novel polypeptides
JP2025128164A (ja) 抗trem2抗体の使用方法
US20250122296A1 (en) Bispecific antibody and use thereof
KR20200041835A (ko) 재조합 이중특이적 항체
CN113677703A (zh) 多肽
EP4594345A1 (en) Protease-activated polypeptides
US20240239912A1 (en) Targeted reduction of activated immune cells
IL301513A (en) Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
CN114616247B (zh) Ox40/pd-l1双特异性抗体
CN118434767A (zh) 新型多肽
HK40066344B (en) Ox40/pd-l1 bispecific antibody
HK40066344A (en) Ox40/pd-l1 bispecific antibody
KR20260023010A (ko) 인간 ccr8에 결합하는 항체 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000